CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Secretaria da Saúde (São Paulo - Estado). Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Hemocentro de Ribeirão Preto (Institutional affiliation from the last research proposal) Birthplace: Brazil
Holds a degree in Biological Sciences from the University of São Paulo (USP) (1999), a PhD in Medical Sciences from the Ribeirão Preto Medical School (FMRP) at USP (2006), and a postdoctoral fellowship in Biomedical Sciences from the Department of Clinical Medicine at FMRP (2006-2009). She served as a Senior Researcher at the biotechnology company Vertias, located in the Supera Campus USP incubator (2010-2011). She was a visiting researcher at the Drug Discovery Laboratory at Purdue University, USA (2017-2018), and at the Department of Basic Medical Sciences at Purdue University, USA (2019-2020). She holds an MBA in Innovation Management and Technological Capacity from Fundação Getúlio Vargas (2023). Currently, she is a researcher at the Blood Center of Ribeirão Preto, where she conducts projects in the fields of cell therapy, focusing on genetically modified T and NK cells, production of viral and non-viral vectors, and recombinant factor production. She maintains international collaborations with Purdue University (USA), the Technical University Dresden (Germany), and the University of Queensland (Australia). She is an active member of the management of the Brazilian Association for Cell Therapy (ABTCEL), serving as First Secretary for the 2023-2026 term. Additionally, she is a member of the International Society for Cell and Gene Therapy (ISCT), where she serves as Regional Treasurer for the term from June 2023 to June 2026. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The Nucleus of Cellular Therapy - NuTeC will be founded on the union of the Regional Blood Center of Ribeirão Preto (Hemocentro RP) and Butantan. Hemocentro RP expertise in cellular therapy will be added to Butantan excellence in the development and production of health applied products to develop CAR T cell therapy. The activities to be conducted by NuTeC are aligned with the scope of th…
In recent years, enormous advances have been made in genetic engineering of effector immune cells for cancer therapy. Although chimeric antigen receptors (CARs) have been widely used to redirect autologous T cell specificity against haematological malignancies, yielding impressive clinical results, studies with CAR-modified natural killer (NK) cells are still restricted to preclinical stu…
Hemophilia is a genetic disorder linked to the X chromosome which results in deficiency or abnormality of factor VIII protein (FVIII). The replacement therapy using protein derived from human plasma or recombinant produced in hamster cell lines (CHO and / or BHK) are the only treatment options available. However, one of the largest replacement therapy problems is the formation of inhibito…
The success of CAR-T cells has created enthusiasm to genetically modify NK cells with CAR to increase their ability to eliminate tumor cells. CAR-NK cells have several advantages over CAR-T cells. First, unlike CAR-T cells, CAR-NK cells retain an intrinsic ability to recognize and target tumor cells through their native receptors, making tumor cell evasion less likely through down-regulat…
Despite being successful, we need to overcome the limitations of CAR therapy with T cells so that this immunotherapy can treat more patients with reduced cost and increased biosafety. The implementation of this therapy with NK cells brings the possibility of an "Off the shelf" allogeneic therapy, ready and available for treating patients. In addition to NK cells intrinsically eliminating …
Hematological malignancies represent a significant portion among the diagnoses of neoplastic cells. Adoptive cell therapy with T cells genetically modified to express chimeric antigen receptors(CAR) has revolutionized the field, with promising and impressive results. However, there are still obstacles associated with the use of CAR-modified T cells, such as the need of autologous cells an…
(Only some records are available in English at this moment)
Our research group has dedicated efforts to the implementation of CAR T-cell therapy at the Blood Center-RP. With the support of FAPESP (NPOP project 2020/07055-9), we have made significant progress in the production of lentiviral vectors for the CAR-T cell project, for which later this year we will start the I/II clinical study approved by ANVISA. Since the inception of the NPOP project …
The development of chimeric antigen receptor T cells (CAR-T) therapy brought significant advances in hematological cancers treatment. It combines the cytotoxic activity of autologous T cells with antibody specificity. For refractory or relapsed B-cell malignancies, the CD19 antigen has been the main target explored, as it is expressed mainly in B cells. Despite an increase in remission ra…
Immunotherapy with modified T cells to express chimeric antigen receptor (CAR) has been proven effective in remission of acute lymphoblastic leukemia (ALL) in children and young adults. The CAR possess an extracellular domain derived from antibody variable regions, and intracellular domains of T cell costimulation. CD19 protein has been shown to be an ideal target for therapies with CAR b…
(Only some records are available in English at this moment)
Natural Killer (NK) cells are a promising alternative for chimeric antigen receptor (CAR) therapy over CAR-T cells. Unlike CAR-T cells, CAR-NK cells retain their intrinsic ability to recognize tumor cells through their receptors. Additionally, NK cells have less restrictive HLA compatibility requirements and do not have the potential to cause graft-versus-host disease (GVHD). This makes C…
Chimeric antigen receptor (CAR)-cell based therapies has emerged as a promising strategy in the field of cancer treatment. Natural killer (NK) cells are innate immune cells with the ability to exert rapid cytotoxicity against transformed and virus-infected cells without prior sensitization and in an HLA-unrestricted manner, which makes it a suitable candidate for "off-the-shelf" cancer im…
| 1 / 1 | Ongoing grants |
| 2 / 2 | Completed research grants |
| 5 / 5 | Ongoing scholarships in Brazil |
| 9 / 5 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 2 / 1 | Completed scholarships abroad |
| 20 / 15 | All research grants and scholarships |
| Associated processes | |